BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, December 17, 2025
Home » Topics » Briefs » Other news to note

Other news to note
Other news to note RSS Feed RSS

Other news to note for May 29, 2025

May 29, 2025
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Alvotech, Adalvo, Advanz, Amoytop, Awakn, Coeptis, Drug Farm, Formosa, Iteos, Juno, Monarch, Snap, Solvonis, TQ.
Read More

Other news to note for May 28, 2025

May 28, 2025
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Antylia Scientific, 23andMe, BD, Cardiosense, Smith+Nephew.
Read More

Other news to note for May 28, 2025

May 28, 2025
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Altamira, Ayrmid, Bioinvent, Biolinerx, Boundless Bio, Galmed, Hansa, Novartis, Rheacell, Regulus, Sanofi, Xoma.
Read More

Other news to note for May 28, 2025

May 28, 2025
Additional early-stage research and drug discovery news in brief, from: Faron Pharmaceuticals, Glyconex, Poxel.
Read More

Other news to note for May 27, 2025

May 27, 2025
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Ainnova, Avant Technologies.
Read More

Other news to note for May 27, 2025

May 27, 2025
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Curatis.
Read More

Other news to note for May 27, 2025

May 27, 2025
Biopharma happenings in Asia-Pacific including deals and partnerships, grants, preclinical data and other news in brief: AFT, Crispr Therapeutics, Hyloris, Pfizer, Rani, Sirius Therapeutics, SK Bioscience.
Read More

Other news to note for May 23, 2025

May 23, 2025
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Halo Labs, Onconetix, Qiagen, Regeneron, Sanofi, Viz.ai, Waters.
Read More

Other news to note for May 23, 2025

May 23, 2025
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: AFT, Biodexa, Eikon, Eli Lilly, Emtora, Hyloris, Inside, OSE, Senti.
Read More

Other news to note for May 23, 2025

May 23, 2025
Additional early-stage research and drug discovery news in brief, from: Connect Biopharma, Gri Bio, Marker Therapeutics, Pasithea Therapeutics, Rein Therapeutics.
Read More
Previous 1 2 … 30 31 32 33 34 35 36 37 38 … 1382 1383 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 16, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 16, 2025.
  • Novo Nordisk semaglutide pill

    CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

    BioWorld
    A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing